Genscript Biotech Corporation (HKG:1548)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
11.79
+0.52 (4.61%)
Jun 18, 2026, 4:08 PM HKT

Genscript Biotech Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Genscript Biotech stock has a consensus rating of "Strong Buy" and an average price target of $17.68. The average 1-year stock price forecast is 49.96% higher than the current stock price, while the lowest is $15.50 (+31.47%) and the highest is $21.02 (+78.29%).

Price Target: $17.68 (+49.96%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$15.50$17.68$17.15$21.02
Change+31.47%+49.96%+45.46%+78.29%
* Price targets were last updated on May 14, 2026.

Analyst Ratings

The average analyst rating for Genscript Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingDec '25Jan '26Feb '26Mar '26Apr '26Jun '26
Strong Buy888666
Buy222222
Hold000000
Sell000000
Strong Sell000000
Total101010888

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
Guotai Haitong
No rating
Guotai Haitong
Buy
Maintains
$25.57
BuyMaintains$25.57+116.88%May 14, 2026
Jefferies
Jefferies
Buy
Maintains
$15.50
BuyMaintains$15.50+31.47%Apr 3, 2026
Unknown Analyst
J.P. Morgan
No rating
J.P. Morgan
Buy
Maintains
$24.00$20.00
BuyMaintains$24.00$20.00+69.64%Mar 19, 2026
Unknown Analyst
CICC
No rating
CICC
Buy
Maintains
$17.90
BuyMaintains$17.90+51.82%Mar 19, 2026
Unknown Analyst
Huatai Securities
No rating
Huatai Securities
Buy
Maintains
$16.26
BuyMaintains$16.26+37.91%Mar 18, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
815.78M
from 959.53M
Decreased by -14.98%
Revenue Next Year
931.12M
from 815.78M
Increased by 14.14%
EPS This Year
0.03
from 0.11
Decreased by -67.17%
EPS Next Year
0.06
from 0.03
Increased by 79.71%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
490.10M625.70M560.48M594.49M959.53M815.78M
Revenue Growth
25.39%27.67%-10.42%6.07%61.40%-14.98%
Gross Profit
282.52M304.08M270.63M272.13M553.20M379.54M
Gross Margin
57.65%48.60%48.29%45.77%57.65%46.53%
Operating Income
-379.29M-437.98M26.19M9.28M255.25M67.00M
Net Income
-358.71M-226.85M-95.48M2.96B-532.83M74.80M
EPS
----0.110.03
EPS Growth
----282.18%-67.17%
Forward PE
----41.9943.61
Free Cash Flow
-176.43M-342.98M-305.28M425.25M-67.82M127.00M
No. Analysts
-----7
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High902.5M
Avg815.8M
Low785.9M

Revenue Growth

Revenue Growth202620272028
High
-5.9%
Avg
-15.0%
Low
-18.1%

EPS Forecast

EPS202620272028
High0.05
Avg0.03
Low0.02

EPS Growth

EPS Growth202620272028
High
-53.4%
Avg
-67.2%
Low
-81.0%